Replimune Group, Inc. (NASDAQ:REPL) Receives $17.29 Average PT from Analysts

Shares of Replimune Group, Inc. (NASDAQ:REPL) have received an average recommendation of “Buy” from the eight analysts that are currently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $17.29.

A number of research analysts recently weighed in on the company. Jefferies Financial Group boosted their price target on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. JPMorgan Chase & Co. boosted their target price on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. BMO Capital Markets raised their price target on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a report on Friday, November 22nd. Finally, HC Wainwright restated a “buy” rating and set a $17.00 target price on shares of Replimune Group in a report on Friday, November 22nd.

Insiders Place Their Bets

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the sale, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.80% of the stock is owned by company insiders.

Institutional Trading of Replimune Group

A number of institutional investors and hedge funds have recently made changes to their positions in REPL. Point72 DIFC Ltd bought a new position in Replimune Group during the 2nd quarter worth $57,000. Arizona State Retirement System bought a new position in shares of Replimune Group during the second quarter worth about $108,000. Quest Partners LLC increased its holdings in shares of Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after acquiring an additional 3,150 shares during the period. Erste Asset Management GmbH bought a new stake in Replimune Group in the 3rd quarter valued at about $133,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Replimune Group by 82.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock valued at $144,000 after purchasing an additional 5,926 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Trading Up 0.5 %

NASDAQ REPL opened at $12.62 on Wednesday. The company has a 50-day moving average of $12.44 and a 200-day moving average of $11.01. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00. The company has a market cap of $863.42 million, a P/E ratio of -4.14 and a beta of 1.26.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. As a group, equities analysts predict that Replimune Group will post -2.91 earnings per share for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.